Cipla Q2 profit seen down 13%, lower Nexium sales may hit margin

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Pharmaceutical firm Cipla's second quarter profit is seen falling 13.4 percent year-on-year to Rs 373.34 crore on dismal operational performance. However, revenue may increase 9 percent to Rs 3,763.2 crore compared with year-ago period, according to average of estimates of analysts polled by CNBC-TV18.

Domestic business contributes 40 percent to sales and the rest is export.

The growth in revenue growth is likely on account of low base in Q2FY16 & consolidation of Invagen (recent US acquisition) sales. Export formulations are likely to grow around 12-14 percent to around Rs 2,050-2,100 crore in September quarter.

Domestic business may grow around 12-14 percent to over Rs 1,400 crore YoY, driven by respiratory segment growth. Export API sales may be muted with a 3-4 percent growth YoY.

Operating profit is likely to decline 16.1 percent year-on-year to Rs 662.3 crore and margin may shrink 527 basis points to 17.6 percent in Q2 due to lower Nexium sales.